Medication to treat Hodgkin's disease
Sintilimab , sold under the brand Tyvyt among others, is a medication used to treat Hodgkin's disease ,[2] and has been approved in China .[3]
It is a fully human IgG4 monoclonal antibody [4] that binds to programmed cell death protein 1 .[5]
It was jointly developed by Innovent Biologics[6] and Eli Lilly.[7]
Medical uses
Sintilimab is medication that is indicated for the treatment of relapsed or refractory classical Hodgkin's lymphoma [8] after failure of at least second-line systemic chemotherapy.[5]
Side effects
Common side effects include fever , thyroid dysfunction , elevation of liver enzymes, and lung inflammation .[9]
Research
Currently, more than 20 clinical trials are ongoing to evaluate the anti-tumor effect of sintilimab injection, either as monotherapy or in combination with other agents, on a variety of solid tumors.[10] In January 2019, the result of the registration trial of sintilimab in people with refractory or relapsed classical Hodgkin's lymphoma was published.[8]
References
^ "anti-PD-1 monoclonal antibody IBI308" . NCI Drug Dictionary . National Cancer Institute . 2011-02-02.
^ "Antibody Drug Conjugates Market Growth Forecast Analysis by Manufacturers, Regions, Type and Application to 2026" . Reuters . October 24, 2018.
^ "NMPA Approves Tyvyt For Hodgkin's lymphoma Read" . Asian Scientist Magazine . January 9, 2019.
^ Ying K, Xu N, Jiang H, Liu Y, Zhou H, Wang S (2018). "OA08 Efficacy and Safety of Sintilimab Combined with 1st Line Chemotherapy in Advanced Squamous Cell Non-small Cell Lung Cancer" . Journal of Thoracic Oncology . 13 (12): S1047. doi :10.1016/j.jtho.2018.10.018 . Retrieved Dec 1, 2018 .
^ a b Hoy SM (February 2019). "Sintilimab: First Global Approval". Drugs . 79 (3): 341–346. doi :10.1007/s40265-019-1066-z . PMID 30742278 . S2CID 59945274 .
^ "Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company" . SEC.gov . December 20, 2018.
^ "Sintilimab - Eli Lilly/Innovent Biologics" . Adis Insight . Springer Nature Switzerland AG. 28 March 2019.
^ a b Ansell SM (January 2019). "Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma". The Lancet. Haematology . 6 (1): e2–e3. doi :10.1016/S2352-3026(18)30210-2 . PMID 30612711 . S2CID 58561198 .
^ A first-in-human phase 1a trial of sintilimab (IBI308) . 2018 ASCO Annual Meeting. American Society of Clinical Oncology . 12 October 2019.
^ Innovent Biologics, Inc. "Innovent Organized a Forum Discussing the Pending Launch of its Anti PD-1 Tyvyt® (Sintilimab injection)" . PR NewsWire (Press release). Retrieved Feb 22, 2019 .